Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

MET Targeted Fibronectin Protein Scaffolds

Technology #20150118

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
FibronectinHGF
Categories
Researchers
Ben Hackel, Ph.D.
Assistant Professor, Department of Chemical Engineering and Materials Science, College of Science and Engineering
External Link (www.cems.umn.edu)
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

Patent or Other Protection

Protein Scaffolds Bind to Hepatocyte Growth Factor Receptor

Non-immunoglobulin based fibronectin protein scaffolds that bind specifically to hepatocyte growth factor receptor (MET) can be used for molecular tumor imaging and targeted therapy. The non-naturally occurring protein scaffold includes a stable framework and loop region engineered to specifically bind MET. Its small size (94 amino acids) enables improved distribution and tissue and/or tumor penetration, which may result in more specific and sensitive cancer diagnoses and better outcomes. In addition, the technology shows potential for use as a targeted therapy.

MET Specific Imaging Applications

MET is an important cancer driver and biomarker, and while some therapeutics that target MET have been developed, no MET-specific imaging agents currently exist. The scaffolds developed in this technology provide non-invasive, whole body assessments of MET expression, with low toxicity and rapid clearance from the body. These scaffolds can enable early cancer detection, as well as better patient stratification.

BENEFITS AND FEATURES:

  • Small size (94 amino acids)
  • Excellent physiological distribution
  • Penetrates tissue/tumors
  • May result in earlier diagnoses
  • Non-immunoglobulin based
  • Low toxicity and rapid clearance from the body
  • Non-invasive whole body assessment of MET expression

APPLICATIONS:

  • Patient stratification
  • Treatment monitoring
  • Early cancer diagnosis
  • Targeting for molecular imaging
  • Targeted therapy

Phase of Development - Proof of Concept